Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLVICROHN: Confocal endomicroscopy with fluorescein vs pathology at ileal resection margins in Crohn's disease
2024-517220-19-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluorescein in Crohn's disease, sponsored by CHU Amiens-Picardie. Primary endpoint: Primary: Concordance of microscopic inflammation status of ileal mucosal resection margin. Planned start Aug 2024; status: authorised.
02
Drugs
fluorescein
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-517220-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517220-19-00.